3-chloro-5-nitro-1,2-benzothiazole-1,1-dioxide | 92083-84-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: 3-chloro-5-nitro-1,2-benzothiazole-1,1-dioxide
• 英文别名: 3-Chloro-5-nitro-1,2-benzothiazole 1,1-dioxide
• CAS: 92083-84-6
• 化学式: C₇H₃ClN₂O₄S
• 分子量: 246.631
• InChiKey: UNBZZTRIBZDGSW-UHFFFAOYSA-N

物化性质

• 沸点：
  465.5±47.0 °C(Predicted)
• 密度：
  1.92±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  101
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-chloro-5-nitro-1,2-benzothiazole-1,1-dioxide 在 ammonium hydroxide 、 sodium dithionite 作用下， 以 1,4-二氧六环 、 丙酮 为溶剂， 反应 7.0h， 生成 3-N-(4-methylphenyl)-1,1-dioxo-1,2-benzothiazole-3,5-diamine
  参考文献：
  名称：

  Structure-based design and synthesis of novel pseudosaccharine derivatives as antiproliferative agents and kinase inhibitors

  摘要：

  This study is concerned with the implementation of structure-based techniques for the design of new heterocyclic compounds based on pseudosaccharine scaffold with protein kinase inhibition activity. This nucleus was exploited based on the well-known quinazoline core and its interactions with several protein kinases. Two series of compounds employing this new scaffold were synthesized and evaluated at enzymatic and cellular levels. Compound 9b displayed broad spectrum antiproliferative activity on NCI 60-cell lines panel with mean GI(50) of 5.4 mu M. Investigation of the molecular mechanism showed probable inhibitory activity against Src kinase. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.09.039
• 作为产物：
  描述：

  4-硝基-2-甲苯胺 在 chromium(VI) oxide 、 盐酸 、 五氯化磷 、 硫酸 、 碳酸氢铵 、 sodium nitrite 作用下， 反应 75.0h， 生成 3-chloro-5-nitro-1,2-benzothiazole-1,1-dioxide
  参考文献：
  名称：

  Structure-based design and synthesis of novel pseudosaccharine derivatives as antiproliferative agents and kinase inhibitors

  摘要：

  This study is concerned with the implementation of structure-based techniques for the design of new heterocyclic compounds based on pseudosaccharine scaffold with protein kinase inhibition activity. This nucleus was exploited based on the well-known quinazoline core and its interactions with several protein kinases. Two series of compounds employing this new scaffold were synthesized and evaluated at enzymatic and cellular levels. Compound 9b displayed broad spectrum antiproliferative activity on NCI 60-cell lines panel with mean GI(50) of 5.4 mu M. Investigation of the molecular mechanism showed probable inhibitory activity against Src kinase. (C) 2012 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2012.09.039

文献信息

• ＹＡＰ/ＴＡＺ-ＴＥＡＤ 상호작용의 억제제인 신규 화합물 및 악성 중피종의 치료에서의 이들의 용도
  申请人：INVENTIVA 엥방티바(520140524752)

  公开号：KR20190137803A

  公开（公告）日：2019-12-11

  본 발명은 화학식: 의 화합물에 관한 것이며, 여기서 R 내지 R은 설명부에 정의된 바와 같다. 이들 화합물은 YAP/TAZ-TEAD 상호작용의 억제제로서 유용하다.

  本发明涉及化学式中的化合物，其中R至R如描述部分中所定义。这些化合物对YAP/TAZ-TEAD相互作用的抑制剂具有用处。
• Histamine H2 receptor antagonists of the benzisothiazole amino and benzthiadiazine amino series
  申请人：BEECHAM GROUP PLC

  公开号：EP0105732A2

  公开（公告）日：1984-04-18

  Compounds of formula (I), or a pharmaceutically acceptable salt, quaternised derivative, N-oxide or solvate thereof: wherein: R1 is hydrogen, halogen, hydroxy, C1-4 alkyl, C1-4 alkoxy, or amino or guanidino, the or any amino moiety being optionally substituted by one or two C1-4 alkyl optionally substituted by halogen, or an aminomethylene group of formula (a), in which R2 and R3 are the same or different and are hydrogen, C1-4 alkyl, C3-6 cycloalkyl, C3-6 cycloalkyl-C1-4 alkyl or phenyl C1-4 alkyl, or R2 and R3 together with the nitrogen atom to which they are attached are morpholino, pyrrolidino or piperidino; Ar is furandiyl, thiophendiyl, phenylene, pyridinediyl, pyrimidinediyl, thiazolediyl, thiadiazolediyl or imidazolediyl; a is 0 or an integer 1 or 2; b is an integer from 2 to 5; and Het is a bicyclic heteroaryl group of formula (b) or (c), in which R4 and R5 are the same or different and are hydrogen, halogen, C1-5 alkyl, trifluoromethyl, nitro, cyano, hydroxy, C1-5 alkoxy, C1-5 alkylthio, carboxy, amino, aminocarbonyl, aminocarbonylamino, amino-thiocarbonylamino, aminosulphonyl, C1-5 alkylsulphonyl, C1-6 alkylsulphinyl, C1-5 alkylsulphonylamino, C1-6 alkyluslphinylamino, phenylsulphonyl, phenylsulphinyl or are a group of formula (d) or (e), in which R9 is hydrogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, phenyl, phenoxy or phenylthio, Y is oxygen or sulphur and Z is oxygen, sulphur or N-R10, R10 being hydrogen or C1-5 alkyl, the C1-6 alkyl group or the C1-6 alkyl moiety of any of the foregoing C1-6 alkyl-containing groups for R4 and R5 being optionally substituted by phenyl, the amino group or the amino moiety of any of the foregoing amino-containing groups for R4 and R5 being optionally substituted by one or two C1-6 alkyl, phenyl or phenyl-C1-4 alkyl or optionally N-disubstituted by C4-5 polymethylene, and the phenyl moity of any of the foregoing phenyl-containing groups for R4 and R5 being optionally substituted by C1-6 alkyl, C1-6 alkoxy, halogen, nitro or trifluoromethyl, one of Rs and Rs is hydrogen, C1-6 alkyl, C1-6 alkanoyl, C1-6 alkylsulphonyl, C1-6 alkoxycarbonyl or phenoxycarbonyl, benzyloxycarbonyl, phenyl, phenylsulphonyl or phenyl C1-4 alkyl, the phenyl moiety being optionally substituted by benzoyl, C1-6 alkyl, C1-4 alkoxy, halogen, nitro or trifluoromethyl, and the other of R6 and R8 together with R7 is a bond, and n is O or an integer 1 or 2.

  式 (I) 化合物或其药学上可接受的盐、季铵盐衍生物、N-氧化物或溶液： 其中 R1 是氢、卤素、羟基、C1-4 烷基、C1-4 烷氧基或氨基或胍基，其中或任何氨基可任选被一个或两个任选被卤素取代的 C1-4 烷基或式（a）的氨基亚甲基取代、 其中 R2 和 R3 相同或不同，且为氢、C1-4 烷基、C3-6 环烷基、C3-6 环烷基-C1-4 烷基或苯基 C1-4 烷基，或 R2 和 R3 连同其所连接的氮原子为吗啉基、吡咯烷基或哌啶基； Ar 是呋喃二基、噻吩二基、亚苯基、吡啶二基、嘧啶二基、噻唑二基、噻二唑二基或咪唑二基； a 是 0 或整数 1 或 2； b 是 2 至 5 的整数；以及 Het 是式 (b) 或 (c) 的双环杂芳基、 其中 R4 和 R5 相同或不同，并且是氢、卤素、C1-5 烷基、三氟甲基、硝基、氰基、羟基、C1-5 烷氧基、C1-5 烷硫基、羧基、氨基、氨基羰基、氨基羰基氨基、氨基-硫代羰基氨基、氨基-硫代羰基氨基、氨磺酰，C1-5 烷基磺酰基，C1-6 烷基亚磺酰基，C1-5 烷基亚磺酰氨基，C1-6 烷基亚磺酰氨基，苯基磺酰基，苯基亚磺酰基或为式 (d) 或 (e) 的基团、 其中 R9 是氢、C1-6 烷基、C1-6 烷氧基、C1-6 烷硫基、苯基、苯氧基或苯硫基，Y 是氧或硫，Z 是氧、硫或 N-R10，R10 是氢或 C1-5 烷基，R4 和 R5 的 C1-6 烷基或前述任何含 C1-6 烷基的基团的 C1-6 烷基分子可选择被苯基取代、R4 和 R5 的氨基或前述任何含氨基基团的氨基基团可选择被一个或两个 C1-6 烷基、苯基或苯基-C1-4 烷基取代，或可选择被 C4-5 聚亚甲基 N-二取代、以及 R4 和 R5 的任何前述含苯基的基团的苯基可选被 C1-6 烷基、C1-6 烷氧基、卤素、硝基或三氟甲基取代，Rs 和 Rs 中的一个为氢、C1-6 烷基、C1-6 烷酰基、C1-6 烷基磺酰基、C1-6 烷氧羰基或苯氧羰基、苄氧羰基、苯基、苯磺酰基或苯基 C1-4 烷基，苯基可任选被苯甲酰基、C1-6 烷基、C1-4 烷氧基、卤素、硝基或三氟甲基取代，R6 和 R8 中的另一个与 R7 一起为键，n 为 O 或 1 或 2 的整数。
• NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA.
  申请人：Inventiva

  公开号：EP3606921B1

  公开（公告）日：2022-06-01
• NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA
  申请人：INVENTIVA

  公开号：US20200115353A1

  公开（公告）日：2020-04-16

  The invention relates to compounds of formula: wherein R 1 to R 7 are as defined in the description. These compounds are useful as inhibitors of the YAP/TAZ-TEAD interaction.
• US4590192A
  申请人：——

  公开号：US4590192A

  公开（公告）日：1986-05-20